Importance Neonatal abstinence syndrome, which occurs as a result of in utero opioid
exposure, affects between 6.0 and 20 newborns per 1000 live US births. There is substantial …

Objectives: The prevalence of opioid use disorder (OUD) during pregnancy is increasing.
Practical recommendations will help providers treat pregnant women with OUD and reduce …

Maternal use of certain drugs during pregnancy can result in transient neonatal signs
consistent with withdrawal or acute toxicity or cause sustained signs consistent with a lasting …

The infant exposed to opioids in utero frequently presents a challenge to the neonatal care
provider in the assessment and treatment of symptoms of Neonatal Abstinence Syndrome …

Neonatal abstinence syndrome (NAS) secondary to in-utero opioid exposure is an
increasing problem. Variability in assessment and treatment of NAS has been attributed to …

Background Current pharmacologic treatment of the neonatal abstinence syndrome with
morphine is associated with a lengthy duration of therapy and hospitalization …

The formulation of medicines for children remains a challenge. An ideal pediatric formulation
must allow accurate dose administration and be in a dosage form that can be handled by the …

Neonatal abstinence syndrome is defined by signs and symptoms of withdrawal that infants
develop after intrauterine maternal drug exposure. All infants with documented in utero …

Pain management in the neonatal ICU remains challenging for many clinicians and in many
complex care circumstances. The authors review general pain management principles and …

Importance Incidence of neonatal abstinence syndrome is rising rapidly, and optimal
pharmacotherapy may meaningfully reduce length of treatment. Objective To compare …